Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Infliximab - Janssen Biotech

Drug Profile

Infliximab - Janssen Biotech

Alternative Names: cA2; CenTNF; Remicade; TA-650

Latest Information Update: 02 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Centocor
  • Developer Centocor; Janssen Biotech; Merck & Co; Mitsubishi Tanabe Pharma Corporation; National Jewish Medical and Research Center; Xian-Janssen
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucocutaneous lymph node syndrome; Crohn's disease; Juvenile rheumatoid arthritis; Ankylosing spondylitis; Behcet's syndrome; Sarcoidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Behcet's syndrome; Crohn's disease; Mucocutaneous lymph node syndrome; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Discontinued Berylliosis; Hepatitis C; Pyoderma

Most Recent Events

  • 02 Jul 2019 Infliximab is not yet available for Crohn's disease and Ulcerative colitis in Taiwan
  • 08 May 2019 Centocor and Oregon Health and Science University withdraw a clinical trial in Crohn's disease (Newly diagnosed) in USA due to lack of enrolment (NCT01266785)
  • 13 Jul 2018 Janssen Korea completes the phase III BEGIN trial in Behcet's syndrome in South Korea (IV) (NCT02505568)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top